1832 Asset Management L.P. Apellis Pharmaceuticals, Inc. Transaction History

1832 Asset Management L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$76.68 - $93.31 $40.7 Million - $49.5 Million	530,800 Added 405.5%	661,700 $60.3 Million
Q1 2023 May 12, 2023	BUY	$46.59 - $66.96 $6.1 Million - $8.77 Million	130,900 New	130,900 $8.63 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $3.94 Million - $6.14 Million	88,100 New	88,100 $6.02 Million

310

113M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.29B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on 1832 Asset Management L.P. with notifications on news.